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Abstract
Background & Aims: Copeptin is a stable cleavage product of the arginine vasopressin (AVP) precursor and is equimolarly
secreted with AVP. Copeptin is currently considered a reliable prognostic marker in a wide variety of diseases other than cir-
rhosis. We aimed to investigate the association between severity of cirrhosis and copeptin concentrations and to confirm
whether copeptin is of prognostic significance in cirrhosis. Methods: One hundred and eighty-four cirrhotic patients hospi-
talized in two tertiary referral centres were studied. Serum copeptin was measured in samples obtained at hospital admis-
sion. Differences in serum copeptin between Child-Pugh classes were evaluated using the Kruskal–Wallis test. Cox
proportional hazard regression and Kaplan–Meier analyses were performed to evaluate associations of copeptin and other
possible prognostic factors with 6- and 12-month mortality. Results: Median serum copeptin (interquartile range) increased
significantly through Child-Pugh classes A [5.4 (3.1–10.7) pmol/L], B [9.6 (6.0–17.3) pmol/L] and C [13.8 (5.8–34.1) pmol/L,
P < 0.01]. Patients with serum copeptin >12.3 pmol/L displayed significantly higher mortality rates at 6 and 12 months as
compared to those with serum copeptin ≤12.3 pmol/L (Log-rank test: P < 0.01). Serum copeptin >12.3 pmol/L was signifi-
cantly associated with mortality, particularly at 6 months, independently of age, clinical parameters and Model for End stage
Liver Disease (MELD), MELD-sodium and Child-Pugh score. Conclusions: Serum copeptin concentration increases signifi-
cantly along with the severity of cirrhosis as defined by the Child-Pugh classification. A high serum copeptin concentration
predicts survival, particularly at 6 months, independently of liver-specific scoring systems in a heterogeneous population of
hospitalized cirrhotic patients.
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Advanced cirrhosis is characterized by haemodynamic
impairment leading to the development of a hyperdy-
namic circulation defined as a decreased systemic vascu-
lar resistance and mean arterial blood pressure (MAP)
and an increased cardiac output (1). The severity of
circulatory derangement has been found to predict
survival in cirrhosis (2). Currently, several liver-specific
scoring systems are used to assess prognosis in cirrhosis,
such as the Model for End stage Liver Disease (MELD),
sodium MELD (MELD-Na) and Child-Pugh (CP)
score. These scores do characterize the severity of the
underlying liver disease, but do not take into account
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the degree of circulatory derangement. Arginine vaso-
pressin (AVP) is a key regulator in hemodynamic
homeostasis and may therefore be interesting as a
potential prognostic marker in cirrhosis. However, AVP
measurements are not useful in clinical practice due to
its instability in serum and its poor reproducibility (3).
Copeptin is a stable cleavage product of the AVP pre-
cursor and is secreted together with AVP in equimolar
amounts (4, 5). Serum copeptin concentration is
increased in the event of systemic inflammation and is
of prognostic significance in a wide variety of diseases
(6–11). However, only a few studies have assessed the
association between serum copeptin concentration and
haemodynamic changes in cirrhotic patients (12, 13).
So far, one study investigated the prognostic signifi-
cance of copeptin in the setting of cirrhosis using a
combined endpoint of death or liver transplantation
(LT) (14). In the present study, we aim to investigate
whether copeptin is of prognostic significance on trans-
plant-free survival in cirrhosis, independently of clinical
parameters and liver-specific prognostic scores.
Methods
Patients
This study was conducted in Liver Units of two tertiary
referral centres, one in the Netherlands and one in
France, with approval of the local ethics committee’s
(France: CCP Est-II (ref:11/634); the Netherlands:
approval for the Liver Diseases Biobank by the Medical
Ethics Committee (MDL 005NV/nv; 3.4120/09/FB/jr)).
Informed consent was obtained from each patient
included in the study and the study protocol conforms
to the ethical guidelines of the 1975 Declaration of Hel-
sinki. A total of 184 hospitalized cirrhotic patients were
studied. In the Netherlands, 61 cirrhotic patients hospi-
talized between October 1994 and April 2011 with a
serum sample available for copeptin measurement were
included. In France, 123 consecutive patients were
recruited from September 2011 till June 2012. Details
on this cohort have been recently reported (14). Serum
samples for copeptin measurement were drawn at
hospital admission for either elective screening for LT
or for acute decompensation of cirrhosis. Demographics
and clinical characteristics were collected at admission.
The presence of renal failure (RF) was defined as a
serum creatinine > 133 lmol/L. Severity of liver disease
was assessed using MELD, MELD-Na and CP scores.
Laboratory measurements
In both centres, serum copeptin measurements were per-
formed in 50 ll samples using an immunoassay in the
chemiluminescence-coated tube format (B.R.A.H.M.S.,
Kryptor, GmbH, Henningsdorf, Germany). The reference
range of serum copeptin in healthy individuals is 1–12
pmol/L with median values of <5 pmol/L (15, 16).
Statistical analysis
Differences in baseline characteristics between centres
were evaluated using the Mann–Whitney U-test, Stu-
dent’s t-test or Chi-square test when appropriate. The
Kruskal–Wallis test was used to evaluate differences in
serum copeptin concentration between CP-classes. Bon-
ferroni’s correction was applied for within-group com-
parison. Spearman’s correlation analysis was performed
to explore correlations between serum copeptin concen-
tration and laboratory and clinical data. Optimal cut-off
points of serum copeptin and C-reactive protein (CRP)
concentration, MAP, MELD, MELD-Na and CP score in
predicting mortality at 6 and 12 months, were deter-
mined using the Youden Index. Values exceeding these
optimal cut-off points are hereinafter referred to as
‘high’ and values equal to or below these optimal cut-off
points as ‘low’. These factors were included in a univari-
ate Cox proportional hazard regression analysis to deter-
mine their association with transplant-free survival at 6
and 12 months of follow-up. Parameters with a P < 0.20
in univariate analyses were entered into the multivariate
analyses. Different models with a maximum of four pre-
dictor variables were fitted, a statistical requirement
because of the limited number of events at both time
points (17). MELD, MELD-Na and CP score were sepa-
rately evaluated with age, serum copeptin, serum CRP,
MAP or the presence of ascites in the multivariate mod-
els. Ascites was not included in the models with CP
score, because ascites is already included in this score.
In order to evaluate whether serum copeptin concen-
tration could give additional prognostic information
next to the MELD, MELD-Na and CP score, survival
analysis at 6 and 12 months stratified according to
serum copeptin concentration and these liver-specific
scores was performed using Kaplan–Meier analysis and
compared using the Log-rank test. Patients were cen-
sored at time of LT or last hospital visit. Sensitivity anal-
Key points
 Serum copeptin concentration increases signifi-
cantly along with the severity of the underlying liver
disease, as defined by the Child-Pugh classification.
 Serum copeptin is significantly associated with 6-
and 12-month mortality in a heterogeneous popula-
tion of hospitalized cirrhotic patients.
 Serum copeptin predicts transplant-free survival
independently of age, clinical parameters and MELD,
MELD-sodium and Child-Pugh score, particularly at
6 months and to a lesser extent also at 12 months.
 Mortality rates in a population of hospitalized cir-
rhotic patients are significantly higher in patients
with a high serum copeptin at admission, even when
excluding patients with renal failure, severe infections
or acute decompensation of cirrhosis.
Liver International (2016)
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 531
Kerbert et al. Transplant-free survival in cirrhosis
yses were performed to investigate whether patients with
a high serum copeptin concentration at admission pre-
dicted 6- and 12-month mortality when excluding
patients with RF, a severe infection or patients admitted
for acute decompensation of cirrhosis. Discrete variables
are shown as counts (percentage) and continuous vari-
ables as mean ± standard deviation (SD). Skewed data
are expressed as median [interquartile range (IQR)]. A
P-value <0.05 was considered statistically significant.
Results
Patient characteristics
Baseline characteristics of the 184 cirrhotic patients hos-
pitalized in the Netherlands and France are shown in
Table 1. In 129 (70.1%) patients, there was a planned
hospital admission either for screening for LT
(n = 55) or routine liver examinations (ultrasonogra-
phy, endoscopy or paracentesis; n = 74). In 51 (29.9%)
patients, the cause of hospitalization was acute decom-
pensation of cirrhosis (nine ascitic decompensation,
four gastrointestinal haemorrhage, five encephalopathy
and two type-1 hepatorenal syndrome) or severe infec-
tion (11 spontaneous bacterial peritonitis, 5 pneumonia,
2 urinary tract infections, 2 skin infections and 11
undetermined infections). Three other patients had
severe acute alcoholic hepatitis and one patient had a
flare-up of autoimmune hepatitis. No patient was lost
to follow-up. Median follow-up time was 300 (161–450)
days.
At 12 months, 33 (17.9%) patients had died and 43
(23.4%) had been transplanted. Deceased patients or
those who underwent LT within 1 year of follow-up had
significantly higher serum copeptin concentrations at
admission as compared to those who survived without a
LT [deceased: 17.5 (7.2–37.9) vs. LT: 11.2 (4.8–28.1) vs.
survivors without LT: 7.9 (4.7–14.3) pmol/L, P < 0.01].
Serum copeptin concentration increased significantly
through CP-classes A [5.4 (3.1–10.7) pmol/L], B [9.6
(6.0–17.3) pmol/L] and C [13.8 (5.8–34.1) pmol/L,
P < 0.01, Fig. 1]. Within-group comparison showed







(n = 123) P-value
Age, years (SD) 55.7 (10.9) 51.0 (11.6) 58.1 (9.8) <0.001
Male gender, n (%) 130 (70.7) 46 (75.4) 84 (68.3) 0.32
Aetiology of cirrhosis, n (%) <0.001
HBV or HCV 21 (11.4) 11 (18.0) 10 (8.1)
Alcohol* 129 (70.1) 26 (42.6) 103 (83.7)
Other 34 (18.5) 24 (39.3) 10 (8.1)
Indication of hospitalization†, n (%) <0.001
Elective 129 (70.1) 55 (90.2) 74 (60.2)
Acute decompensation 20 (10.9) 5 (8.2) 15 (12.2)
Severe infection 31 (16.8) 1 (1.6) 30 (24.4)
Other 4 (2.2) 0 (0.0) 4 (3.3)
Ascites, n (%) 105 (57.1) 41 (67.2) 64 (52.0) 0.47
HRS, n (%) 9 (4.9) 7 (11.5) 2 (1.6) 0.007
MAP (mmHg) 84.8 (75.0–93.3) 84.7 (80.0–93.3) 85.0 (73.3–93.3) 0.21
Copeptin (pmol/L) 9.6 (4.9–20.7) 11.0 (5.2–24.0) 8.9 (4.8–17.5) 0.30
Bilirubin (lmol/L) 43.5 (24.0–100.8) 45 (26.5–84.5) 43 (21–113) 0.65
Sodium (mmol/L) 137.1 (5.1) 138.2 (5.1) 136.6 (5.0) 0.05
Albumin (g/L) 29.8 (7.3) 31.5 (5.8) 28.7 (7.7) 0.021
Creatinine (lmol/L) 81 (65.3–100.8) 86 (68.5–109) 80 (64–96) 0.40
CRP (mg/L) 12 (5–37) 9 (5.5–29) 13 (5–43) 0.32
INR 1.5 (1.2–2.1) 1.3 (1.2–1.4) 1.6 (1.3–2.3) <0.001
MELD score 15.0 (11.3–21.9) 13.5 (11.3–16.9) 17.0 (11.0–24.0) 0.031
MELD-Na score 17.3 (12.1–24.3) 14.9 (11.9–18.1) 18.7 (13.0–25.3) 0.008
Child-Pugh score 9.0 (7.0–10.0) 9.0 (7.0–10.0) 9.0 (6.0–11.0) 0.61
Child-Pugh classes, %
A/B/C 23/38/39 15/54/31 27/30/43 0.006
*Six patients with alcoholic cirrhosis were infected with viral hepatitis C; these patients are included in the alcoholic group.
†‘Elective’ hospital admission is defined as either screening for liver transplantation or a routine liver examination. ‘Acute decompensation’ is defined
as the acute development of a major complication of cirrhosis (i.e. ascites, hepatorenal syndrome, gastrointestinal bleeding or hepatic encephalopa-
thy). Other causes of hospital admission were acute alcoholic hepatitis (n = 3) and a flare-up of autoimmune hepatitis (n = 1).
CRP, C-reactive protein; DBP, diastolic blood pressure; HBV, hepatitis B virus; HCV, hepatitis C virus; HRS, hepatorenal syndrome; INR, international
normalized ratio, MAP, mean arterial pressure; MELD, Model for End stage Liver Disease; MELD-Na, sodium MELD; SBP, systolic blood pressure; SD,
standard deviation.
Data are shown as counts (percentage), mean (standard deviation) or median (interquartile range).
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significant differences between serum copeptin
concentration in CP-A and CP-B (P < 0.01) and
between CP-A and CP-C (P < 0.01). Serum copeptin
concentration did not differ significantly between CP-B
and CP-C (P = 0.35). Patients admitted for acute
decompensation of cirrhosis had more advanced stages
of cirrhosis than electively admitted patients [CP-A/B/
C: 0%/20% (n = 11)/80% (n = 44) vs. 32.6% (n = 42)/
45.7% (n = 59)/21.7% (n = 28); P < 0.01] and had also
higher serum copeptin concentrations [13.3 (5.9–34.1)
vs. 8.5 (4.4–17.12) pmol/L, P < 0.01]. In patients with
ascites at hospital admission (n = 105), a significantly
higher serum copeptin concentration was measured as
compared to patients without ascites [13.3 (6.9–31.8)
vs. 6.1 (3.4–11.3) pmol/L, P < 0.01]. Serum copeptin
concentration was also significantly higher in patients
with RF (n = 17) at hospital admission as compared to
patients without RF [36.8 (25.3–49.6) vs. 8.7 (4.6–16.7)
pmol/L, P < 0.01]. Serum copeptin concentration was
positively correlated with serum total bilirubin
(r = 0.26, P < 0.01), CRP (r = 0.34, P < 0.01), crea-
tinine concentration (r = 0.39, P < 0.01), INR
(r = 0.25, P < 0.01) and MELD (r = 0.38, P < 0.01),
MELD-Na (r = 0.38, P < 0.01) and CP (r = 0.30,
P < 0.01) scores. No significant correlations with
copeptin were found for MAP and serum sodium con-
centration.
Univariate analysis
Optimal cut-off points for serum copeptin and CRP
concentration, MAP and MELD, MELD-Na and CP
score in predicting mortality at 6 and 12 months are
shown in Table 2A. Patients with a low serum copeptin
concentration showed a significantly better transplant-
free survival at both 6 and 12 months (Log-rank test:
P < 0.01). Transplant-free survival at 6 months strati-
fied according to serum copeptin concentration is
shown in Fig. 2. In the univariate analyses, a high serum
copeptin and CRP concentration and high MELD,
MELD-Na and CP scores all showed a significant associ-
ation with mortality at these time points. A significant
association was also found with age, a low MAP (at
12 months) and the presence of ascites (Table 2A).
Patients with both a low serum copeptin concentra-
tion and high MELD, MELD-Na or CP score displayed
the best transplant-free survival rates at 6 and 12 months
as compared to (i) patients with both a high serum
copeptin concentration and MELD, MELD-Na or CP
score, (ii) patients with a low serum copeptin concentra-
tion and high MELD, MELD-Na or CP score and (iii)
patients with a high serum copeptin concentration and
low MELD, MELD-Na or CP score at time of hospital
admission (Table 2A). Figure 3 shows transplant-free
survival curves at 6 months, stratified according to both
serum copeptin and MELD score. Figure S1A and S1B
show transplant-free survival curves at 6 months, strati-
fied according to serum copeptin and MELD-Na score
and serum copeptin and CP score, respectively.
Multivariate analysis
Table 2B shows three multivariate Cox-regression
models, in which copeptin is evaluated together with
age, CRP and MELD (model 1), MELD-Na (model 2)
or CP score (model 3), respectively. A high serum
copeptin concentration at admission was found to be
significantly associated with mortality at 6 and
12 months of follow-up, independently of age, high
serum CRP and MELD, MELD-Na or CP score
(Table 2B). Only at 12 months of follow-up, no signif-
icant association of high serum copeptin with mortal-
ity was found in the model with CP score. Separate
multivariate Cox-regression models were fitted in
order to evaluate the prognostic ability of high serum
copeptin independently of the presence of ascites or a
low MAP, in addition to age, high MELD or high
MELD-Na score. A high serum copeptin concentration
remained an independent predictor of mortality at 6
and 12 months of follow-up in these models. Ascites
was not an independent prognostic factor at 6 or
12 months, whereas MAP only showed an independent
association with mortality at 12 months (Table S1).
Sensitivity analysis
Sensitivity analyses were performed in order to assess
the robustness of the prognostic value of copeptin in
specific groups of cirrhotic patients. Survival analysis
was performed in patients without RF, severe infections
or acute decompensation of cirrhosis. When restricting
survival analysis to patients without RF (n = 167), 6-
Fig. 1. Serum copeptin concentration in the three cirrhotic groups
according to the Child-Pugh classification. Box plots represent
serum copeptin concentrations in Child-Pugh classes A–C. Boxes
are defined by interquartile ranges, and error bars represent the
lowest and highest observed values within 1.5 times the length of
the box. Data points outside this range are shown individually.
Horizontal lines denote median values.
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and 12-month survival rate was significantly lower in
patients with a high serum copeptin concentration
(n = 57) as compared to patients with a low serum
copeptin concentration (n = 110; 6 months: 70.2% vs.
94.5%, P < 0.01; 12 months: 68.4% vs. 90.0%,
P < 0.01). In patients without severe infections
Table 2. Univariate (A) and multivariate (B) Cox regression analyses of factors influencing the 6- and 12-month transplant-free survival in
184 cirrhotic patients
6-month mortality 12-month mortality
HR (95% CI) P-value HR (95% CI) P-value
A. Univariate
Age 1.06 (1.02–1.10) 0.004 1.06 (1.02–1.10) 0.001
Ascites 3.06 (1.23–7.63) 0.016 2.95 (1.32–6.57) 0.008
MAP
Cut-off point (mmHg) 83 78
High MAP 0.47 (0.21–1.05) 0.065 0.38 (0.19–0.76) 0.006
CRP
Cut-off point (mg/L) 16.5 16.5
High CRP 6.89 (2.59–18.29) <0.001 4.72 (2.19–10.18) <0.001
Copeptin
Cut-off point (pmol/L) 12.3 12.3
High copeptin 6.21 (2.49–15.48) <0.001 3.90 (1.89–8.05) <0.001
MELD score
Cut-off point 18 24
High MELD score 4.47 (1.99–10.04) <0.001 6.55 (3.27–13.12) <0.001
MELD-Na score
Cut-off point 17 17
High MELD-Na score 12.76 (3.02–54.04) 0.001 6.40 (2.47–16.61) <0.001
Child-Pugh score
Cut-off point 10 9
High Child-Pugh score 3.82 (1.77–8.25) 0.001 5.72 (2.47–13.24) <0.001
Copeptin and MELD score*
Low copeptin + high MELD 0.68 (0.08–5.86) 0.72 5.00 (1.48–16.57) 0.009
High copeptin + low MELD 2.11 (0.57–7.84) 0.27 2.34 (0.88–6.25) 0.09
High copeptin + high MELD 10.41 (3.79–28.57) <0.001 13.79 (5.70–33.36) <0.001
Copeptin and MELD-Na score†
Low copeptin + high MELD-Na 8.26 (0.99–68.61) 0.051 4.90 (1.35–17.81) 0.024
High copeptin + low MELD-Na 2.91 (0.18–46.56) 0.45 1.97 (0.33–11.82) 0.16
High copeptin + high MELD-Na 33.77 (4.50–253.50) 0.001 13.27 (3.91–45.04) 0.001
Copeptin and CP score‡
Low copeptin + high Child-Pugh 0.00 (0.00–0.00) 0.98 2.86 (0.92–8.88) 0.07
High copeptin + low Child-Pugh 2.62 (0.88–7.80) 0.08 1.30 (0.33–5.20) 0.71
High copeptin + high Child-Pugh 11.53 (4.35–30.54) <0.001 10.68 (4.23–27.00) <0.001
B. Multivariate
Model 1
Age 1.05 (1.01–1.10) 0.010 1.06 (1.02–1.10) 0.002
High CRP 3.81 (1.37–10.62) 0.010 2.56 (1.11–5.89) 0.027
High copeptin 3.36 (1.26–8.98) 0.016 2.20 (1.00–4.82) 0.050
High MELD score 2.72 (1.12–6.59) 0.027 4.38 (2.03–9.47) <0.001
Model 2
Age 1.04 (1.00–1.09) 0.030 1.05 (1.01–1.09) 0.008
High CRP 2.88 (1.02–8.12) 0.046 2.49 (1.08–5.74) 0.033
High copeptin 3.59 (1.39–9.31) 0.009 2.47 (1.14–5.31) 0.021
High MELD-Na score 5.86 (1.30–26.30) 0.021 3.61 (1.31–9.97) 0.013
Model 3
Age 1.05 (1.01–1.09) 0.017 1.07 (1.03–1.12) <0.001
High CRP 4.14 (1.50–11.45) 0.006 3.11 (1.39–6.96) 0.006
High copeptin 3.65 (1.38–9.67) 0.009 1.84 (0.82–4.12) 0.14
High Child-Pugh score 2.16 (0.95–4.92) 0.066 5.26 (2.22–12.47) <0.001
‘Low’ and ‘high’ refers to values below and above the optimal cut-off point as defined using the Youden index respectively. *,†,‡The reference
groups were patients with low serum copeptin and *low MELD score, †low MELD-Na score, and ‡low Child-Pugh score.
CI, confidence interval; CP, Child-Pugh; CRP, C-reactive protein; HR, hazard ratio; MAP, mean arterial blood pressure; MELD, Model for End stage
Liver Disease; MELD-Na, sodium MELD.
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(n = 154), survival rates at 6 and 12 months were signif-
icantly lower in patients with a high serum copeptin
concentration (n = 54) as compared to patients with a
low serum copeptin concentration (n = 100; 6 months:
79.6% vs. 95.0%, P < 0.01; 12 months: 77.8% vs. 90.0%,
P = 0.04). When restricting survival analysis to patients
who were electively admitted (n = 129), patients with a
high serum copeptin concentration (n = 84), showed
significantly lower survival rates at 6 months as com-
pared to patients with a low serum copeptin concentra-
tion (n = 45; 6 months: 84.4% vs. 95.2%, P = 0.04;
12 months: 82.2% vs. 89.3%, P = 0.26).
Discussion
In this study, we show that serum copeptin concentra-
tion is elevated in a large population of hospitalized,
cirrhotic patients with varying degrees of disease sever-
ity. The highest serum copeptin concentrations were
observed in patients with CP-C as compared to CP-A
and CP-B patients, which is in accordance with previous
recent findings (12–14). Patients who died or who
received a LT within 1 year of follow-up had a signifi-
cantly higher serum copeptin concentration at admis-
sion as compared to those who survived without a LT.
Moreover, we show that serum copeptin is a predictor
of short-term (6 months) and long-term (12 months)
mortality, independently of age, serum CRP, MAP (at
12 months), the presence of ascites and liver-specific
prognostic scores.
An increased intrahepatic vascular resistance and
portal inflow and a decreased systemic vascular resis-
tance contribute to the development of portal hyperten-
sion in cirrhosis. In advanced stages of cirrhosis, further
reduction of systemic vascular resistance cannot be
compensated by additional increases in cardiac output,
leading to the activation of counter regulatory systems,
such as the renin-angiotensin-aldosterone system, sym-
pathetic nervous system and to the release of AVP by
the posterior pituitary gland. The release of AVP into
the blood stream leads to vasoconstriction and renal
water retention (18). Because of the key role of AVP in
haemodynamic homeostasis, exploration of AVP as a
potential biomarker of haemodynamic derangement
and prognosis in cirrhosis may be relevant. However,
AVP molecules have a short half-life and more than
90% is bound to platelets in the circulation. Therefore,
AVP measurements are not useful in clinical practice
(3). Copeptin, a stable cleavage product of the C-term-
inal part of the AVP precursor, is secreted together with
AVP in equimolar proportions and is not bound to pla-
telets in the circulation (5). Serum copeptin is therefore
a surrogate marker of AVP and is a promising prognos-
tic marker in cirrhosis, as haemodynamic derangement
is reported to be related to the severity of hepatic dys-
function and survival (2). Recent studies have shown
associations between high serum copeptin levels and
systemic haemodynamic changes, such as portal hyper-
tension, a hepatic venous pressure gradient >12 mmHg
and a decreased cardiac output (12, 13). It has also been
reported that high serum copeptin concentrations are
associated with the presence of ascites in cirrhosis (13).
Currently, copeptin is considered a reliable prognostic
factor in a wide variety of diseases, such as diabetes,
heart failure, sepsis and lower respiratory tract infection
(6–11). To date, one study has investigated the prognos-
tic value of copeptin in the setting of cirrhosis (14).
However, in that study, the combined endpoint ‘mortal-
ity or LT’ was used. The current study is the first one to
evaluate copeptin as a potential marker of increased risk
of mortality without LT in cirrhosis and the results cor-
roborate that copeptin could serve as an independent
prognostic marker in cirrhosis. In addition, we found
that copeptin might give additional prognostic informa-
tion next to the widely used MELD score and MELD-Na
score.
Fig. 2. Transplant-free survival at 6 months of follow-up of 184
hospitalized cirrhotic patients stratified according to serum copep-
tin concentration. Patients are censored at time of liver transplanta-
tion or last hospital visit.
Fig. 3. Transplant-free survival at 6 months of follow-up of 184
hospitalized cirrhotic patients stratified according to serum copep-
tin concentration and Model for End stage Liver Disease (MELD)
score. Patients are censored at time of liver transplantation or last
hospital visit.
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In cirrhosis, pro-inflammatory cytokines have been
found to be elevated and are related to circulatory
derangement (19, 20). Patients with cirrhosis have an
increased risk of developing systemic inflammation as
a result of increased intestinal permeability and bacte-
rial translocation (21). CRP is a well-known marker
of inflammation and has recently demonstrated its
prognostic significance in predicting short-term mor-
tality in cirrhotic patients (22, 23). It has also been
found that serum CRP and copeptin concentrations
are both associated with disease severity and prognosis
in non-cirrhotic patients with sepsis (11, 24). The
results of the present study confirm the prognostic
value of CRP in cirrhotic patients. We have also
found a significant positive correlation between serum
copeptin and CRP, indicating that copeptin is more
than a potential biomarker of haemodynamic
derangement. This might be explained by the fact that
the release of AVP, and thus of copeptin, may also be
triggered by exposure to stress, such as severe bacte-
rial infection and sepsis. Another explanation may be
that elevation of both serum CRP and copeptin is
induced by common precipitating events, as exposure
to bacteria and their endotoxins may exacerbate circu-
latory derangements and thus lead to an increase in
serum copeptin concentration (12, 13, 25). In the cur-
rent study, serum copeptin predicted mortality in
hospitalized cirrhotic patients independently of CRP,
also when restricting survival analysis to patients
without severe infections at hospital admission.
A strength of our study is that the study population
consisted of a heterogeneous group of cirrhotic
patients, with a wide variety of disease severity and dif-
ferent indications of admission. The differences
observed in baseline characteristics between the Dutch
and French cohort, as indicated in Table 1, are also
likely to be related to differences in these specific indi-
cations of hospital admission between the two centres.
In the Dutch cohort, a vast majority of the patients
were electively admitted for screening for LT, whereas
in the French cohort a relatively large number of the
cirrhotic patients were admitted for acute decompensa-
tion or a severe infection. In addition, there were evi-
dent differences in the aetiological background of
cirrhosis between the two centres. The release of AVP,
and thus of copeptin, is triggered under several condi-
tions, such as pain, bleeding, nausea, infection, hypoxia
and hypovolaemia (26). These factors are more likely
to be present in patients suffering from acute decom-
pensation of cirrhosis or sepsis than in electively
admitted patients. Despite the heterogeneity of the
study population, serum copeptin concentration inde-
pendently predicted mortality, even when restricting
survival analysis to the electively admitted patients.
This finding shows the generalizability of the prognos-
tic value of copeptin in cirrhosis.
This study has a number of limitations. Firstly,
blood samples for serum copeptin measurements were
only drawn at admission. After 12 months of follow-
up, the independent predictive value of copeptin dis-
appeared when adjusting for the MELD and CP score.
This might be explained by changes in the course of
liver disease progression over time. Prospectively con-
ducted studies providing serial copeptin measurements
are needed to evaluate potential effects of variation in
serum copeptin concentration over time on survival.
Secondly, we did not extensively investigate the rela-
tionship between renal function and serum copeptin
concentration. Several studies have shown an inverse
correlation between copeptin concentrations and renal
function (15, 27, 28). In the current study, this inverse
relationship between copeptin concentration and renal
function was confirmed by a strong positive correla-
tion between copeptin and creatinine concentration
and the fact that serum copeptin was significantly
higher in patients with RF as compared to patients
without RF. The interpretation of serum copeptin con-
centration in cirrhotic patients should take into
account renal function, but further research is needed
to investigate whether a high serum copeptin concen-
tration is causally related to renal impairment. Never-
theless, when restricting survival analysis to patients
without RF at hospital admission, patients with a high
serum copeptin concentration still displayed signifi-
cantly higher mortality rates as compared to patients
with a low serum copeptin concentration. Finally, we
were not able to define the presence of acute-on-
chronic liver failure (ACLF) in patients admitted for
acute decompensation of cirrhosis in our present
study cohort. ACLF is the most common cause of
death in patients with decompensated cirrhosis (29)
and it would be interesting to investigate whether
there is an association between copeptin levels and the
risk of development of ACLF. Because of the systemic
vasoconstrictor effects of AVP, which are thought to
contribute to the development of organ failures,
copeptin levels might also be a potential predictor of
the development of ACLF and survival in these
patients.
In conclusion, serum copeptin concentration, as an
indirect marker of circulatory dysfunction, increases sig-
nificantly along with the severity of cirrhosis. More
importantly, copeptin appears to predict 6-month and
12-month survival, independently of liver-specific scor-
ing systems in a large and heterogeneous population of
hospitalized cirrhotic patients.
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CI, confidence interval; CP, Child Pugh; CRP, C-reactive protein; HR, hazard ratio; 
MAP, mean arterial blood pressure; MELD, Model of End stage Liver Disease; 
MELD-Na, sodium MELD. 
“Low” and “high” values refers to values below and above the optimal cut-off point as 
defined using the Youden index, respectively. 
  
2) Figure legend of supplementary figure 1. 
 
Supplementary figure S1. Transplant-free survival at 6 months of follow-up of 184 
hospitalized cirrhotic patients stratified according to serum copeptin concentration 
and MELD-Na (A) and serum copeptin and Child-Pugh score (B). 
Patients are censored at time of liver transplantation or last hospital visit. 
 


